Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases
I'm PortAI, I can summarize articles.
William Blair analyst Sami Corwin maintains a Buy rating on Kyverna Therapeutics (KYTX) due to promising results from the miv-cel (KYV-101) trial in Stiff Person Syndrome, supporting a Biologics License Application. The therapy shows potential as the first FDA-approved CAR-T for autoimmune diseases. Despite stock price increases and regulatory uncertainties, frequent FDA interactions reduce risk. H.C. Wainwright also reiterates a Buy rating with a $20 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments